US Patent

US8802628 — Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration

Formulation · Assigned to Forest Laboratories Holdings ULC · Expires 2031-10-30 · 5y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable solid formulations of linaclotide suitable for oral administration, including methods for preparing them.

USPTO Abstract

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Drugs covered by this patent

Patent Metadata

Patent number
US8802628
Jurisdiction
US
Classification
Formulation
Expires
2031-10-30
Drug substance claim
No
Drug product claim
Yes
Assignee
Forest Laboratories Holdings ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.